BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$9.84
arrow_upward
+4.90%(+0.46) 1D
$9.86
arrow_upward
+0.23% (+0.022)bedtimeAfter hours
Closed: Aug 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$9.33
High
$9.86
Low
$9.28
Mkt. cap
2.51B
Avg. vol.
4.37M
Volume
4.01M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.56
Shares outstanding
255.54M
No. of employees
435
Open
$9.33
High
$9.86
Low
$9.28
Mkt. cap
2.51B
Avg. vol.
4.37M
Volume
4.01M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.56
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 week ago
BCRX Q1 2026 Earnings: EPS Miss of -281.82% Drags Shares Down 3.04% - Earnings Miss Streak
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com
AI content may include mistakes. Learn more